Test Bank For Clayton’s Basic Pharmacology for Nurses 19th
gw gw gw gw gw gw gw gw
Edition By Michelle J. Willihnganz, Samuel L. Gurevitz, Bruce
gw gw gw gw gw gw gw gw gw
Clayton Complete
gw gw
Page 1 of 408
,Chapter 01: Drug Definitions, Standards, and Information Sources
gw gw gw gw gw gw gw
Willihnganz: Clayton’s Basic Pharmacology for Nurses, 19th Edition
gw gw gw gw gw gw gw gw
MULTIPLE gwCHOICE
1. Which gwname gwidentifies gwa gwdrug gwlisted gwbygwthe gwUS
Food gwand gwDrug gwAdministration gw(FDA)?
gw
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS: gwC
The gwofficial gwname gwis gwthe g w name gwunder gwwhich gwa gwdrug
gwis gwlisted gwby gwthe gwFDA. gwThe gwbrand gwname, gwor
gwtrademark, gwis gwthe gwname gwgiven gwto gwa gwdrug gwby gwits
gwmanufacturer. gwThe gwnonproprietary, gwor gwgeneric, gwname
gwis gwprovided gwby gwthe gwUnited gwStates gwAdopted gwNames
gwCouncil.
DIF: Cognitive gwLevel: gwKnowledge REF: g w p. gw9
OBJ: gw1NAT: gwNCLEX gwClient gwNeeds gwCategory: gwSafe,
gwEffective gwCare gwEnvironment gwTOP: g w Nursing gwProcess gwStep:
gwAssessment CON:
gwPatient gwEducation
2. Which gwsource gwcontains gwinformation gwspecific gwto gwnutritional gwsupplements?
a. USP gwDictionary gwof gwUSAN gw &gwInternational gwDrug gwNames
b. Natural gwMedicines gwComprehensive gwDatabase
c. United gwStates gwPharmacopoeia/National gwFormulary gw(USP gwNF)
d. Drug gwInteraction gwFacts
ANS: gwC
United gwStates gwPharmacopoeia/National gwFormulary gwcontains gwinformation gwspecific gwto
gwnutritional gwsupplements. gwUSP gwDictionary gwof gwUSAN gw& gwInternational gwDrug gwNames gwis
gwa gwcompilation gwof gwdrug gwnames, gwpronunciation gwguide, gwand gwpossible gwfuture gwFDA
gwapproved gwdrugs; gwit gwdoes gwnot gwinclude gwnutritional gwsupplements. gwNatural gwMedicines
gwComprehensive gwDatabase gwcontains
evidence-based gwinformation gwon gwherbal gwmedicines gwand gwherbal gwcombination gwproducts; gwit
gwdoes gwnot gwinclude gwinformation gwspecific gwto gwnutritional gwsupplements. gwDrug gwInteraction
gwFacts gwcontains gwcomprehensive gwinformation gwon gwdrug gwinteraction gwfacts; gwit gwdoes gwnot
gwinclude gwnutritional gwsupplements.
DIF: Cognitive gwLevel: gwKnowledge REF: g w p. gw4 OBJ:
gw3 gwNAT: g w NCLEX gwClient gwNeeds gwCategory: gwPhysiological
gwIntegrity
TOP: g w Nursing gwProcess gwStep: gwAssessment CON: g w Nutrition gw|gwPatient gwEducation
3. Which gwdrug gwreference gwcontains gwdrug gwmonographs gwthat gwdescribe gwall gwdrugs gwin gwa gwtherapeutic
class?
gw
a. Drug gwFacts gwand gwComparisons
Page 2 of 408
,Test gwBank gwFor gwClayton’s gwBasic gwPharmacology gwfor gwNurses gw19th 3
gwEdition
b. Drug gwInteraction gwFacts
c. Handbook gwon gwInjectable gwDrugs
d. Martindale—The gwComplete gwDrug gwReference
ANS: g w A
Drug gwFacts gwand gwComparisons gwcontains gwdrug gwmonographs gwthat gwdescribe gwall
gwdrugs gwin gwa gwtherapeutic gwclass. gwMonographs gware gwformatted gwas gwtables gwto gwallow
gwcomparison gwof gwsimilar gwproducts, gwbrand gwnames, gwmanufacturers, gwcost gwindices,
gwand gwavailable gwdosage gwforms gwOnline gwversion gwis gwavailable.
DIF: Cognitive gwLevel: gwKnowledge REF: g w p. gw4 gwTable gw1.2
OBJ: g w g w 3 NAT: g w NCLEX gwClient gwNeeds gwCategory: gwPhysiological gwIntegrity
TOP: g w Nursing gwProcess gwStep: gwAssessment CON: g w Safety gw|gwPatient gwEducation gw|gwClinical gwJudgment
4. Which gwdrug gwreference gwcontains gwmonographs gwabout gwvirtually gweverygwsingle-entitygwdrug
available gwin gwthe gwUnited gwStates gwand gwdescribes gwtherapeutic gwuses gwof gwdrugs, gwincluding
gw
approved gwand gwunapproved gwuses?
gw
a. Martindale: gwThe gwComplete gwDrug gwReference
b. AHFS gwDrug gwInformation
c. Drug gwReference
d. Drug gwFacts gwand gwComparisons
ANS: g w B
AHFS gwDrug gwInformation gwcontains gwmonographs gwabout gwvirtually gwevery gwsingle-entity
gwdrug gwavailable gwin gwthe gwUnited gwStates gwand gwdescribes gwtherapeutic gwuses gwof gwdrugs,
gwincluding gwapproved gwand gwunapproved gwuses.
DIF: Cognitive gwLevel: gwKnowledge REF: g w p. gw4 gwTable gw1.2
OBJ: g w g w 3 NAT: g w NCLEX gwClient gwNeeds gwCategory: gwPhysiological gwIntegrity
TOP: g w Nursing gwProcess gwStep: gwPlanning CON: g w Safety gw|gwPatient gwEducation gw|gwClinical gwJudgment
5. Which gwonline gwdrug gwreference gwmakes gwavailable gwto gwhealthcare gwproviders gwand gwthe
gwpublic gwa gwstandard, gwcomprehensive, gwup-to-date gwlook gwup gwand gwdownloadable gwresource
gwabout gwmedicines?
a. American gwDrug gwIndex
b. American gwHospital gwFormulary
c. DailyMed
d. Drug gwReference
ANS: gwC
DailyMed gwmakes gwavailable gwto gwhealthcare gwproviders gwand gwthe gwpublic gwa gwstandard,
gwcomprehensive, gwup-to-date gwlook gwup gwand gwdownloadable gwresource gwabout gwmedicines. gwThe
gwAmerican gwDrug gwIndex gwis gwnot gwappropriate gwfor gwpatient gwuse. gwThe gwAmerican gwHospital
gwFormulary gwis gwnot gwappropriate gwfor gwpatient gwuse. gwThe gwdrug gwreference gwis gwnot
gwappropriate gwfor gwpatient gwuse.
DIF: Cognitive gwLevel: gwKnowledge REF: g w p. gw3 gw| gwp. gw4
OBJ: gw3 gwNAT: g w NCLEX gwClient gwNeeds gwCategory:
gwPhysiological gwIntegrity
TOP: gwNursing gwProcess gwStep: gwImplementation
CON: g w Safety gw|gwPatient gwEducation gw| gwClinical gwJudgment
6. Which gwlegislation gwauthorizes gwthe gwFDA gwto gwdetermine gwthe gwsafetygwof gwa gwdrug gwbefore gwits gwmarketing?
a. Federal gwFood, gwDrug, gwand gwCosmetic gwAct gw(1938)
b. Durham gwHumphrey gwAmendment gw(1952)
, Test gwBank gwFor gwClayton’s gwBasic gwPharmacology gwfor gwNurses gw19th 4
gwEdition
c. Controlled gwSubstances gwAct gw(1970)
d. Kefauver gwHarris gwDrug gwAmendment gw(1962)
ANS: g w A
The gwFederal gwFood, gwDrug, gwand gwCosmetic gwAct gwof gw1938 gwauthorized gwthe gwFDA gwto
gwdetermine gwthe gwsafety gwof gwall gwdrugs gwbefore gwmarketing. gwLater gwamendments gwand gwacts
gwhelped gwtighten gwFDA gwcontrol gwand gwensure gwdrug gwsafety. gwThe gwDurham gwHumphrey
gwAmendment gwdefines gwthe gwkinds gwof gwdrugs gwthat gwcannot gwbe gwused gwsafely gwwithout
gwmedical gwsupervision gwand gwrestricts gwtheir gwsale gwto gwprescription gwby gwa gwlicensed
gwpractitioner. gwThe gwControlled gwSubstances gwAct gwaddresses gwonly gwcontrolled gwsubstances gwand
gwtheir gwcategorization. gwThe gwKefauver gwHarris gwDrug gwAmendment gwensures gwdrug gwefficacy
gwand gwgreater gwdrug gwsafety. gwDrug gwmanufacturers gware gwrequired gwto gwprove gwto gwthe gwFDA
gwthe gweffectiveness gwof gwtheir gwproducts gwbefore gwmarketing gwthem.
DIF: Cognitive gwLevel: gwKnowledge REF: g w p. gw5 gwTable gwl.3
OBJ: g w 5 NAT: gwNCLEX gwClient gwNeeds gwCategory: gwPhysiological
gwIntegrity gwTOP: g w Nursing gwProcess gwStep: gwAssessment
CON: g w Safety gw|gwPatient gwEducation gw| gwEvidence gw| gwHealth gwCare gwLaw
7. Which gwclassification gwdoes gwmeperidine gw(Demerol) gwfall gwunder?
a. I
b. II
c. III
d. IV
ANS: g w B
Meperidine gw(Demerol) gwis gwa gwSchedule gwII gwdrug; gwit gwhas gwa gwhigh gwpotential gwfor gwabuse gwand
gwmay gwlead gwto gwsevere gwpsychological gwand gwphysical gwdependence. gwSchedule gwI gwdrugs gwhave
gwhigh gwpotential gwfor gwabuse gwand gwno gwrecognized gwmedical gwuse. gwSchedule gwIII gwdrugs gwhave
gwsome gwpotential gwfor gwabuse. gwUse gwmay gwlead gwto gwlow gwto gwmoderate gwphysical gwdependence
gwor gwhigh gwpsychological gwdependence. gwSchedule gwIV gwdrugs gwhave gwlow gwpotential gwfor
gwabuse. gwUse gwmay gwlead gwto gwlimited gwphysical gwor gwpsychological gwdependence.
DIF: Cognitive gwLevel: gwKnowledge REF: g w p. gw10 OBJ:
gw2 gwNAT: g w NCLEX gwClient gwNeeds gwCategory: gwSafe, gwEffective gwCare
gwEnvironment
TOP: g w Nursing gwProcess gwStep: gwAssessment CON: g w Patient gwEducation gw|gwAddiction gw|gwPain
8. Which gwaction gwwould gwthe gwFDA gwtake gwto gwexpedite gwdrug gwdevelopment gwand gwapproval gwfor gwan
outbreak gwof gwsmallpox?
gw
a. List gwsmallpox gwas gwa gwhealth gworphan gwdisease.
b. Omit gwthe gwpreclinical gwresearch gwphase.
c. Extend gwthe gwclinical gwresearch gwphase.
d. Fast gwtrack gwthe gwinvestigational gwdrug.
ANS: gwD
Once gwthe gwInvestigational gwNew gwDrug gwApplication gwhas gwbeen gwapproved, gwthe gwdrug gwcan
gwreceive gwhighest gwpriority gwwithin gwthe gwagency, gwwhich gwis gwcalled gwfast gwtracking. gwA
gwsmallpox gwoutbreak gwwould gwbecome gwa gwpriority gwconcern gwin gwthe gwworld. gwOrphan
gwdiseases gware gwnot gwresearched gwin gwa gwpriority gwmanner. gwPreclinical gwresearch gwis gwnot
gwomitted. gwExtending gwany gwphase gwof gwthe gwresearch gwwould gwmean gwa gwlonger gwtime gwto
gwdevelop gwa gwvaccine. gwThe gwFDA gwmust gwensure gwthat gwall gwphases gwof gwthe gwpreclinical gwand
gwclinical gwresearch gwphase gwhave gwbeen gwcompleted gwin gwa gwsafe gwmanner.
DIF: Cognitive gwLevel: gwKnowledge REF: g w gw p. gw7 OBJ: gw 5
gw gw gw gw gw gw gw gw
Edition By Michelle J. Willihnganz, Samuel L. Gurevitz, Bruce
gw gw gw gw gw gw gw gw gw
Clayton Complete
gw gw
Page 1 of 408
,Chapter 01: Drug Definitions, Standards, and Information Sources
gw gw gw gw gw gw gw
Willihnganz: Clayton’s Basic Pharmacology for Nurses, 19th Edition
gw gw gw gw gw gw gw gw
MULTIPLE gwCHOICE
1. Which gwname gwidentifies gwa gwdrug gwlisted gwbygwthe gwUS
Food gwand gwDrug gwAdministration gw(FDA)?
gw
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS: gwC
The gwofficial gwname gwis gwthe g w name gwunder gwwhich gwa gwdrug
gwis gwlisted gwby gwthe gwFDA. gwThe gwbrand gwname, gwor
gwtrademark, gwis gwthe gwname gwgiven gwto gwa gwdrug gwby gwits
gwmanufacturer. gwThe gwnonproprietary, gwor gwgeneric, gwname
gwis gwprovided gwby gwthe gwUnited gwStates gwAdopted gwNames
gwCouncil.
DIF: Cognitive gwLevel: gwKnowledge REF: g w p. gw9
OBJ: gw1NAT: gwNCLEX gwClient gwNeeds gwCategory: gwSafe,
gwEffective gwCare gwEnvironment gwTOP: g w Nursing gwProcess gwStep:
gwAssessment CON:
gwPatient gwEducation
2. Which gwsource gwcontains gwinformation gwspecific gwto gwnutritional gwsupplements?
a. USP gwDictionary gwof gwUSAN gw &gwInternational gwDrug gwNames
b. Natural gwMedicines gwComprehensive gwDatabase
c. United gwStates gwPharmacopoeia/National gwFormulary gw(USP gwNF)
d. Drug gwInteraction gwFacts
ANS: gwC
United gwStates gwPharmacopoeia/National gwFormulary gwcontains gwinformation gwspecific gwto
gwnutritional gwsupplements. gwUSP gwDictionary gwof gwUSAN gw& gwInternational gwDrug gwNames gwis
gwa gwcompilation gwof gwdrug gwnames, gwpronunciation gwguide, gwand gwpossible gwfuture gwFDA
gwapproved gwdrugs; gwit gwdoes gwnot gwinclude gwnutritional gwsupplements. gwNatural gwMedicines
gwComprehensive gwDatabase gwcontains
evidence-based gwinformation gwon gwherbal gwmedicines gwand gwherbal gwcombination gwproducts; gwit
gwdoes gwnot gwinclude gwinformation gwspecific gwto gwnutritional gwsupplements. gwDrug gwInteraction
gwFacts gwcontains gwcomprehensive gwinformation gwon gwdrug gwinteraction gwfacts; gwit gwdoes gwnot
gwinclude gwnutritional gwsupplements.
DIF: Cognitive gwLevel: gwKnowledge REF: g w p. gw4 OBJ:
gw3 gwNAT: g w NCLEX gwClient gwNeeds gwCategory: gwPhysiological
gwIntegrity
TOP: g w Nursing gwProcess gwStep: gwAssessment CON: g w Nutrition gw|gwPatient gwEducation
3. Which gwdrug gwreference gwcontains gwdrug gwmonographs gwthat gwdescribe gwall gwdrugs gwin gwa gwtherapeutic
class?
gw
a. Drug gwFacts gwand gwComparisons
Page 2 of 408
,Test gwBank gwFor gwClayton’s gwBasic gwPharmacology gwfor gwNurses gw19th 3
gwEdition
b. Drug gwInteraction gwFacts
c. Handbook gwon gwInjectable gwDrugs
d. Martindale—The gwComplete gwDrug gwReference
ANS: g w A
Drug gwFacts gwand gwComparisons gwcontains gwdrug gwmonographs gwthat gwdescribe gwall
gwdrugs gwin gwa gwtherapeutic gwclass. gwMonographs gware gwformatted gwas gwtables gwto gwallow
gwcomparison gwof gwsimilar gwproducts, gwbrand gwnames, gwmanufacturers, gwcost gwindices,
gwand gwavailable gwdosage gwforms gwOnline gwversion gwis gwavailable.
DIF: Cognitive gwLevel: gwKnowledge REF: g w p. gw4 gwTable gw1.2
OBJ: g w g w 3 NAT: g w NCLEX gwClient gwNeeds gwCategory: gwPhysiological gwIntegrity
TOP: g w Nursing gwProcess gwStep: gwAssessment CON: g w Safety gw|gwPatient gwEducation gw|gwClinical gwJudgment
4. Which gwdrug gwreference gwcontains gwmonographs gwabout gwvirtually gweverygwsingle-entitygwdrug
available gwin gwthe gwUnited gwStates gwand gwdescribes gwtherapeutic gwuses gwof gwdrugs, gwincluding
gw
approved gwand gwunapproved gwuses?
gw
a. Martindale: gwThe gwComplete gwDrug gwReference
b. AHFS gwDrug gwInformation
c. Drug gwReference
d. Drug gwFacts gwand gwComparisons
ANS: g w B
AHFS gwDrug gwInformation gwcontains gwmonographs gwabout gwvirtually gwevery gwsingle-entity
gwdrug gwavailable gwin gwthe gwUnited gwStates gwand gwdescribes gwtherapeutic gwuses gwof gwdrugs,
gwincluding gwapproved gwand gwunapproved gwuses.
DIF: Cognitive gwLevel: gwKnowledge REF: g w p. gw4 gwTable gw1.2
OBJ: g w g w 3 NAT: g w NCLEX gwClient gwNeeds gwCategory: gwPhysiological gwIntegrity
TOP: g w Nursing gwProcess gwStep: gwPlanning CON: g w Safety gw|gwPatient gwEducation gw|gwClinical gwJudgment
5. Which gwonline gwdrug gwreference gwmakes gwavailable gwto gwhealthcare gwproviders gwand gwthe
gwpublic gwa gwstandard, gwcomprehensive, gwup-to-date gwlook gwup gwand gwdownloadable gwresource
gwabout gwmedicines?
a. American gwDrug gwIndex
b. American gwHospital gwFormulary
c. DailyMed
d. Drug gwReference
ANS: gwC
DailyMed gwmakes gwavailable gwto gwhealthcare gwproviders gwand gwthe gwpublic gwa gwstandard,
gwcomprehensive, gwup-to-date gwlook gwup gwand gwdownloadable gwresource gwabout gwmedicines. gwThe
gwAmerican gwDrug gwIndex gwis gwnot gwappropriate gwfor gwpatient gwuse. gwThe gwAmerican gwHospital
gwFormulary gwis gwnot gwappropriate gwfor gwpatient gwuse. gwThe gwdrug gwreference gwis gwnot
gwappropriate gwfor gwpatient gwuse.
DIF: Cognitive gwLevel: gwKnowledge REF: g w p. gw3 gw| gwp. gw4
OBJ: gw3 gwNAT: g w NCLEX gwClient gwNeeds gwCategory:
gwPhysiological gwIntegrity
TOP: gwNursing gwProcess gwStep: gwImplementation
CON: g w Safety gw|gwPatient gwEducation gw| gwClinical gwJudgment
6. Which gwlegislation gwauthorizes gwthe gwFDA gwto gwdetermine gwthe gwsafetygwof gwa gwdrug gwbefore gwits gwmarketing?
a. Federal gwFood, gwDrug, gwand gwCosmetic gwAct gw(1938)
b. Durham gwHumphrey gwAmendment gw(1952)
, Test gwBank gwFor gwClayton’s gwBasic gwPharmacology gwfor gwNurses gw19th 4
gwEdition
c. Controlled gwSubstances gwAct gw(1970)
d. Kefauver gwHarris gwDrug gwAmendment gw(1962)
ANS: g w A
The gwFederal gwFood, gwDrug, gwand gwCosmetic gwAct gwof gw1938 gwauthorized gwthe gwFDA gwto
gwdetermine gwthe gwsafety gwof gwall gwdrugs gwbefore gwmarketing. gwLater gwamendments gwand gwacts
gwhelped gwtighten gwFDA gwcontrol gwand gwensure gwdrug gwsafety. gwThe gwDurham gwHumphrey
gwAmendment gwdefines gwthe gwkinds gwof gwdrugs gwthat gwcannot gwbe gwused gwsafely gwwithout
gwmedical gwsupervision gwand gwrestricts gwtheir gwsale gwto gwprescription gwby gwa gwlicensed
gwpractitioner. gwThe gwControlled gwSubstances gwAct gwaddresses gwonly gwcontrolled gwsubstances gwand
gwtheir gwcategorization. gwThe gwKefauver gwHarris gwDrug gwAmendment gwensures gwdrug gwefficacy
gwand gwgreater gwdrug gwsafety. gwDrug gwmanufacturers gware gwrequired gwto gwprove gwto gwthe gwFDA
gwthe gweffectiveness gwof gwtheir gwproducts gwbefore gwmarketing gwthem.
DIF: Cognitive gwLevel: gwKnowledge REF: g w p. gw5 gwTable gwl.3
OBJ: g w 5 NAT: gwNCLEX gwClient gwNeeds gwCategory: gwPhysiological
gwIntegrity gwTOP: g w Nursing gwProcess gwStep: gwAssessment
CON: g w Safety gw|gwPatient gwEducation gw| gwEvidence gw| gwHealth gwCare gwLaw
7. Which gwclassification gwdoes gwmeperidine gw(Demerol) gwfall gwunder?
a. I
b. II
c. III
d. IV
ANS: g w B
Meperidine gw(Demerol) gwis gwa gwSchedule gwII gwdrug; gwit gwhas gwa gwhigh gwpotential gwfor gwabuse gwand
gwmay gwlead gwto gwsevere gwpsychological gwand gwphysical gwdependence. gwSchedule gwI gwdrugs gwhave
gwhigh gwpotential gwfor gwabuse gwand gwno gwrecognized gwmedical gwuse. gwSchedule gwIII gwdrugs gwhave
gwsome gwpotential gwfor gwabuse. gwUse gwmay gwlead gwto gwlow gwto gwmoderate gwphysical gwdependence
gwor gwhigh gwpsychological gwdependence. gwSchedule gwIV gwdrugs gwhave gwlow gwpotential gwfor
gwabuse. gwUse gwmay gwlead gwto gwlimited gwphysical gwor gwpsychological gwdependence.
DIF: Cognitive gwLevel: gwKnowledge REF: g w p. gw10 OBJ:
gw2 gwNAT: g w NCLEX gwClient gwNeeds gwCategory: gwSafe, gwEffective gwCare
gwEnvironment
TOP: g w Nursing gwProcess gwStep: gwAssessment CON: g w Patient gwEducation gw|gwAddiction gw|gwPain
8. Which gwaction gwwould gwthe gwFDA gwtake gwto gwexpedite gwdrug gwdevelopment gwand gwapproval gwfor gwan
outbreak gwof gwsmallpox?
gw
a. List gwsmallpox gwas gwa gwhealth gworphan gwdisease.
b. Omit gwthe gwpreclinical gwresearch gwphase.
c. Extend gwthe gwclinical gwresearch gwphase.
d. Fast gwtrack gwthe gwinvestigational gwdrug.
ANS: gwD
Once gwthe gwInvestigational gwNew gwDrug gwApplication gwhas gwbeen gwapproved, gwthe gwdrug gwcan
gwreceive gwhighest gwpriority gwwithin gwthe gwagency, gwwhich gwis gwcalled gwfast gwtracking. gwA
gwsmallpox gwoutbreak gwwould gwbecome gwa gwpriority gwconcern gwin gwthe gwworld. gwOrphan
gwdiseases gware gwnot gwresearched gwin gwa gwpriority gwmanner. gwPreclinical gwresearch gwis gwnot
gwomitted. gwExtending gwany gwphase gwof gwthe gwresearch gwwould gwmean gwa gwlonger gwtime gwto
gwdevelop gwa gwvaccine. gwThe gwFDA gwmust gwensure gwthat gwall gwphases gwof gwthe gwpreclinical gwand
gwclinical gwresearch gwphase gwhave gwbeen gwcompleted gwin gwa gwsafe gwmanner.
DIF: Cognitive gwLevel: gwKnowledge REF: g w gw p. gw7 OBJ: gw 5
